Singapore, Nov. 6 -- South Korea-based International Vaccine Institute (IVI) has joined Bayer AG and the Coalition for Epidemic Preparedness Innovations (CEPI) to support Egypt's Minapharm Group in advancing the development of a Bundibugyo ebolavirus vaccine candidate, in response to the current outbreak and to prepare for future ones.

Through its ACHIEVE Africa initiative, IVI will support Minapharm as the vaccine candidate progresses toward clinical evaluation in Africa, working with relevant African health and regulatory institutions.

The vaccine candidate was designed by ProBioGen, a Berlin-based Contract Development and Manufacturing Organisation and one of Minapharm's subsidiaries, using their proprietary Modified Vaccinia Ankara ...